Ruxolitinib plus abemaciclib for myelofibrosis after ruxolitinib
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding abemaciclib to ongoing ruxolitinib can better control myelofibrosis in people who are not getting enough benefit from ruxolitinib alone. It is designed to see safety and response in a specific group with intermediate-2 or high-risk disease and ongoing symptoms or enlarged spleen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older) with primary myelofibrosis or post-PV/post-ET myelofibrosis that needs treatment and is intermediate-1, intermediate-2, or high risk
- You have been taking ruxolitinib for at least 12 weeks, on a stable dose for at least 4 weeks, and your dose is 10 mg or 15 mg twice daily
- Your ruxolitinib treatment isn’t working enough—your spleen is enlarged (at least 5 cm) and/or you still have significant symptoms
- Your general health is good enough for study treatment (ECOG score 0–2) and you have an estimated life expectancy of at least 24 weeks
- Your blood counts and organ function meet lab limits (for example, a minimum neutrophil count and platelet count) and you are not badly recovering from recent chemo or major surgery
- You can follow strict pregnancy-prevention rules and must be willing to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This study tests adding a new drug (pelabresib) to the standard treatment (ruxolitinib) for Japanese people with myelofibrosis. The goal is to see if the combination helps control symptoms like an enlarged spleen.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
Hear when a new Myelofibrosis Due to and Following Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.